Bilateral Half‐Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata

Özdemır, Mustafa; Balevi, Ali

doi:10.1111/pde.13049

Cited by 28 publications

(31 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In an uncontrolled study, 25% showed cosmetically acceptable hair growth; however, it failed to show any therapeutic benefits in 11 AT cases . In a recent half‐head study of pediatric patients, anthralin showed a better therapeutic effect on the treated side than the untreated side . In a RCT comparing anthralin and azelaic acid, both showed the comparable effect .…”

Section: Second‐line Therapiesmentioning

confidence: 99%

Management of alopecia areata: Updates and algorithmic approach

Lee

2017

The Journal of Dermatology

View full text Add to dashboard Cite

Alopecia areata is a chronic, recurrent and non-scarring alopecia. The prognoses of patients are very diverse. The larger the area of hair loss, the poorer the treatment response and greater the probability of chronic disease progression. Numerous treatments have been introduced, but curative treatments have yet to be established. The long-term efficacy of the current treatments is minimal, and the therapeutic response varies widely. Recent clinical trials have attempted to apply therapeutic metrics, such as the Severity of Alopecia Tool, and many have been designed as randomized controlled studies, enabling a more precise evaluation of existing treatments. There have been updates in practice, efficacy or indications of therapeutics that have been previously used. Moreover, the use of novel treatments such as biologics has recently been introduced. Commonly, the most important factor in determining the treatment modality for alopecia areata has been the extent of hair loss. However, if the disease activity is high and likely to progress, combination therapy with adjuvant modalities will be more desirable. This review will discuss the therapeutic effects of existing and newly-introduced treatments based on their quantity, quality of evidence and expected complications. In addition, an algorithmic approach to management of alopecia areata is proposed according to clinical subtype, severity, onset and activity of the disease.

show abstract

Section: Second‐line Therapiesmentioning

confidence: 99%

Management of alopecia areata: Updates and algorithmic approach

Lee

2017

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…25,61 However, both 5% minoxidil and 1-2% topical antraline could be prescribed in these patients. 62 In severe cases of AA, topical immunotherapy (diphenylcyclopropenone), has been used. Although corticosteroid pulse therapy has shown lower adverse effects at low doses.…”

mentioning

confidence: 99%

Alopecia Areata. Current situation and perspectives

et al. 2017

View full text Add to dashboard Cite

Alopecia areata (AA) is a dermatological disease characterized by non-scarring hair loss of the scalp and/or body, with an unpredictable and variable evolution in the patients in which, despite multidisciplinary efforts, its etiology is not entirely known, although some evidence suggests that environmental, immunological and genetic factors could be generating the disease. The aim of this review is to provide an updated panorama of the clinical characteristics, diagnosis and treatment of AA, to analyze the mechanisms that could participate in its etiology, as well as to review some of the most important genetic variants that could confer susceptibility to the development of this disease.

show abstract

“…There is growing evidence of safety and efficacy in treatment of recalcitrant pediatric alopecia areata with emphasis on very thorough washing of any anthralin residue to minimize skin irritation (Ngwanya, ; Özdemir, ; Wu, ).…”

Section: Treatment Strategies In Special Populationsmentioning

confidence: 99%

“…CCS of mild and midpotency are preferred over potent ones. Calcipotriol is not to be applied for children There is growing evidence of safety and efficacy in treatment of recalcitrant pediatric alopecia areata with emphasis on very thorough washing of any anthralin residue to minimize skin irritation (Ngwanya, 2017;Özdemir, 2017;Wu, 2018).…”

Section: Childrenmentioning

confidence: 99%

Practical compendium for psoriasis management

Ibrahim

Amer

Nofal

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Psoriasis management is complex and challenging. It should be tailored for each patient. Treatment strategy differs according to patient's age, sex, disease type, disease severity, burden on patient's quality of life, comorbidities, involvement of specific sites, and pregnancy. The choice of the appropriate therapeutic must take into consideration the availability, the price, and the patient's preferences. It is very important that the chosen treatment is not more unpleasant, intolerable, or dangerous than the disease itself. According to the disease type, severity, and effect on patient's quality of life, dermatologist chooses whether to start with topical therapy, phototherapy or systemic therapy, or a combination of two or more of them. Under each category, there are different types of therapies that can be the first line therapeutics, second line, or even contraindicated. In this compendium, we provide dermatologists with different treatment plans considering all the mentioned variables so that a dermatologist can choose the optimum plan for the patient.

show abstract

Bilateral Half‐Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata

Cited by 28 publications

References 20 publications

Management of alopecia areata: Updates and algorithmic approach

Management of alopecia areata: Updates and algorithmic approach

Alopecia Areata. Current situation and perspectives

Practical compendium for psoriasis management

Contact Info

Product

Resources

About